Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Piramal's second helping

When Nicholas Piramal India Ltd. established its discovery business two years ago, it set itself the goal of bringing a novel drug to the global market by 2010-11. The company thinks its recent deal with Merck & Co. Inc. is likely to get it the rest of the way to the five to eight clinical compounds it figures it needs to reach that goal.

Read the full 643 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers